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Abstract
Background: Extracellular nucleotides play an important role in the regulation of vascular tone
and may be involved in cerebral vasospasm after subarachnoidal haemorrhage. This study was
designed to characterise the contractile P2 receptors in endothelium-denuded human cerebral and
omental arteries. The isometric tension of isolated vessel segments was recorded in vitro. P2
receptor mRNA expression was examined by RT-PCR.
Results: In human cerebral arteries, the selective P2Y6 receptor agonist, UDPβS was the most
potent of all the agonists tested (pEC50 = 6.8 ± 0.7). The agonist potency; UDPβS > αβ-MeATP >
UTPγS > ATPγS > ADPβS = 0, indicated the presence of contractile P2X1 P2Y2, P2Y4 and P2Y6,
but not P2Y1 receptors, in human cerebral arteries. In human omental arteries, UDPβS was
inactive. The agonist potency; αβ-MeATP > ATPγS = UTPγS > ADPβS = UDPβS = 0, indicated the
presence of contractile P2X1, and P2Y2 receptors, but not P2Y1 or P2Y6 receptors, in human
omental arteries. RT-PCR analysis of endothelium-denuded human cerebral and omental arteries
demonstrated P2X1, P2Y1, P2Y2 and P2Y6 receptor mRNA expression. There were no bands for
the P2Y4 receptor mRNA in the omental arteries, while barely detectable in the cerebral arteries.
Conclusions: P2Y6 receptors play a prominent role in mediating contraction of human cerebral
arteries. Conversely, no such effect can be observed in human omental arteries and previous
results confirm the absence of P2Y6 receptors in human coronary arteries. The P2Y6 receptor
might be a suitable target for the treatment of cerebral vasospasm.
Background
There is evidence of the release of adenosine triphosphate
(ATP) from endothelial cells, platelets, and sympathetic
nerves as well as from damaged cells in atherosclerosis,
hypertension, restenosis and ischemia [1]. Uridine tri-
phosphate (UTP) has been shown to be released from en-
dothelial cells in response to flow and shear stress [2], and
it has been isolated from platelets [3]. Since UTP is partic-
ularly present in the brain and has potent vasoconstrictor
actions in human cerebral arteries, it may play a role in
Published: 9 May 2003
BMC Pharmacology 2003, 3:4
Received: 22 January 2003
Accepted: 9 May 2003
This article is available from: http://www.biomedcentral.com/1471-2210/3/4
© 2003 Malmsjö et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/4
Page 2 of 10
(page number not for citation purposes)
cerebral vasospasm after subarachnoidal haemorrhage
[4–6].
Extracellular nucleotides induce vasodilatation by activat-
ing P2Y receptors on endothelial cells, while vasoconstric-
tion is mediated by P2Y and P2X receptors on vascular
smooth muscle cells. When the endothelial function is
damaged in pathological conditions such as subarachnoi-
dal haemorrhage or arteriosclerosis the vasoconstrictor ac-
tions dominate, causing cerebral vasospasm [7].
Recent receptor cloning has proven the existence of sever-
al different P2X and P2Y receptor subtypes, and there is
evidence that five of these elicit vascular response when
stimulated by extracellular nucleotides, namely P2X1,
P2Y1, P2Y2, P2Y4 and P2Y6 [8,9]. Expression of these re-
ceptors in cells has enabled characterisation of their re-
spective pharmacological profile. P2X1  receptors have
been shown by immunohistochemistry to be the domi-
nant P2X receptor on smooth muscle cells in the vascula-
ture [10,11]. P2X1  receptors are activated by αβ-
methylene-adenosine triphosphate (αβ-MeATP) > ATP
with no effect of uridine triphosphate (UDP) or UTP [12].
At the P2Y1 receptor adenosine 5'-O-3-thiodiphosphate
(ADPβS) and adenosine diphosphate (ADP) have greater
potency than ATP, while UTP and UDP are inactive
[13,14]. The P2Y2 receptor is activated with similar poten-
cies by ATP and UTP but not by ADP or UDP; the human
P2Y4 receptor is activated most potently by UTP, less po-
tently by ATP, and not at all by nucleotide diphosphates;
and the P2Y6 receptor is activated most potently by UDP
but weakly by UTP, ADP and ATP [15].
However, the identification of P2 receptors expressed on
smooth muscle cells is difficult particularly because of the
absence of truly selective agonists and antagonists. Ligand
instability complicates the analyses especially when per-
formed in intact tissues as nucleotide triphosphates are
rapidly metabolised by ectonucleotidases on the extracel-
lular surface of cells [16]. In addition, commercial nucle-
otides are impure. Stable nucleotides have recently started
to be used in attempts to pharmacologically define the
P2Y receptor subtypes. These include uridine 5'-O-thiodi-
phosphate (UDPβS), uridine 5'-O-3-thiotriphosphate
(UTPγS), adenosine 5'-O-thiodiphosphate (ADPβS) and
adenosine 5'-O-3-thiotriphosphate (ATPγS) that contain a
modification of the nucleotide triphosphate group in the
form of a thio substitution at the terminal phosphate,
which provides stability to ectonucleotidase action. UT-
PγS is a potent and enzymatically stable agonist at the hu-
man P2Y2 and P2Y4 receptors, while UDPβS has recently
shown to selectively activate the P2Y6 receptors [17,18]. It
is therefore now possible to discriminate between the vas-
cular effects of different pyrimidine activated P2 receptor
subtypes.
In the design of future cerebrovascular therapeutics it is
important that the contractile responses of extracellular
nucleotides is characterised in human subjects. This study
was designed to evaluate the relative contribution of the
different P2Y receptor subtypes that mediate the contrac-
tile response in human cerebral and omental arteries,
which has not been done before by use of the stable pyri-
midines UDPβS and UTPγS.
Results
Vasomotor responses
After endothelium removal, the vasodilatory response to
acetylcholine in UTP preconstricted arteries was abol-
ished, indicating a properly removed endothelium. Fur-
thermore, vascular smooth muscle cell function was
considered intact, since the contractile response to 60
mmol/L K+ was unaffected. P2X receptors were desensi-
tised by addition of 10 µmol/Lαβ-MeATP. This elicited a
transient contraction. After 8 min the tension was back to
baseline and if αβ-MeATP was added a second time, no
contraction could be observed, indicating desensitised
P2X receptors.
The contractile capacity of the arteries was examined by
addition of 60 mmol/L K+. For the cerebral arteries the
contractile response to 60 mmol/L K+ amounted to 2.7 ±
1.3 mN above baseline tension and, for omental arteries,
to 8.2 ± 0.8 mN. The nucleotide-induced contractions
were thereafter calculated as percent of this K+-contraction
in respective vessel segment.
Human cerebral arteries
αβ-MeATP induced potent contractions of the human cer-
ebral arteries, indicating effects of contractile P2X recep-
tors. After P2X receptor desensitisation (see methods),
further experiments were performed to analyse P2Y recep-
tor mediated vasoconstrictions. The endogenous nucle-
otides, UDP and UTP, elicited contractions of similar
potencies (pEC50 = 5.5 ± 0.2 and 5.3 ± 0.2, P = n.s.). Fur-
ther experiments were therefore performed using the sta-
ble nucleotide analogues UDPβS, UTPγS, ATPγS and
ADPβS. Notably, the selective P2Y6  receptor agonist,
UDPβS, was one log unit more potent than UDP in the
human cerebral arteries (pEC50 = 6.8 ± 0.2 and 5.5 ± 0.2,
P < 0.001), making it the most potent of all agonists test-
ed. ATP and ADP induced contractions only at mmol/L
concentrations. The stable purine, ATPγS, induced a con-
siderably more potent contraction than ATP (pEC50 = 3.0
± 0.2 for ATP and 4.8 ± 0.2 for ATPγS, P < 0.001). The AT-
PγS concentration-response curve resembled that of UT-
PγS, indicating involvement of P2Y2 receptors. On the
other hand, ADPβS had no effect, indicating that there are
no contractile P2Y1 receptors.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/4
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In conclusion, the potency order for the agonists in hu-
man cerebral arteries was: UDPβS > αβ-MeATP > UTPγS >
ATPγS > ADPβS = 0, indicating involvement of contractile
P2X1, P2Y2, P2Y4 and P2Y6, but not P2Y1 receptors, in hu-
man cerebral arteries. All data are presented in Table 1. For
data concerning the endogenous nucleotides in the cere-
bral circulation, see Fig 1a. the stable nucleotides, see Fig
2a.
Human omental arteries
αβ-MeATP induced potent contractions of the human
omental arteries, indicating effects of contractile P2X re-
ceptors. After P2X receptor desensitisation (see methods),
further experiments were performed to analyse P2Y recep-
tor mediated vasoconstrictions. The endogenous nucle-
otides, UTP and UDP, only induced contraction at a high
concentration (mM). Conversely, the stable pyrimidines,
UDPβS and UTPγS, had a markedly different pharmaco-
logical profile. Unlike the cerebral arteries, UDPβS was in-
active in the human omental arteries, indicating that there
are no contractile P2Y6 receptors. The potency of UTPγS
was one log unit higher than that for UTP (pEC50 = 4.3 ±
0.1 and 3.3 ± 0.1, P < 0.001), indicating stability to ecto-
nucleotidase activity. UTPγS and ATPγS induced vasocon-
striction might be a result of P2Y2  or P2Y4  receptor
activation in omental arteries. Like in the cerebral arteries,
ADPβS did not induce vasoconstriction in the omental ar-
teries, indicating that contractile P2Y1 receptors do not
play a role.
In conclusion, the potency order for the agonists in the
human omental arteries was; αβ-MeATP > ATPγS = UTPγS
> ADPβS = UDPβS = 0, indicating the presence of contrac-
tile P2X1 and P2Y2 receptors, but not P2Y1 or P2Y6 recep-
tors, in human omental arteries. All data are presented in
Table 1. For data concerning the endogenous nucleotides
in the cerebral circulation, see Fig 1b. the stable nucle-
otides, see Fig 2b.
RT-PCR
Agarose gel electrophoresis of PCR products from en-
dothelium-denuded, human cerebral and omental arter-
ies demonstrated products of the expected size for the
corresponding mRNA encoding human P2X1 (383 base
pairs), P2Y1 (550 base pairs), P2Y2 (432 base pairs) and
P2Y6 receptors (526 base pairs) (Fig. 3). There were no
bands for the P2Y4 receptor mRNA (530 base pairs) in the
omental arteries, while these were barely detected in the
cerebral arteries. No bands were detected in controls with-
out an RT-step.
Discussion
The stable pyrimidines, UTPγS and UDPβS, were here for
the first time used to characterise the P2 receptor subtypes
that mediate vasoconstriction in human cerebral and
omental arteries. The novel findings include that the P2Y6
receptors play a prominent role in mediating contraction
of cerebral arteries. Conversely, no such effect can be ob-
served in omental arteries and previous results confirm
the absence of P2Y6 receptors in human coronary arteries
[26]. The marked effects of the P2Y6 receptor in the cere-
bral circulation might make it a suitable target for treat-
ment of diseases with cerebral vasospasm.
Study of P2Y receptors has been a challenge due to the
paucity of pharmacological tools for identification of re-
ceptor subtypes. Since truly selective antagonists have not
yet been developed, the characterisation of P2Y receptors
has mainly been performed by monitoring agonist re-
sponses. This causes difficulties, as the endogenous nucle-
otides UTP, UDP, ATP and ADP are neither selective nor
stable. However, recent studies present the stable pyrimi-
dines UTPγS, UDPβS as unique pharmacological tools
that facilitate the characterisation of P2Y receptor sub-
types in intact tissues [26,27]. The present results clearly
demonstrate the importance of stable nucleotides in the
characterisation of receptors in tissue preparations with
ectonucleotidase activity: In the cerebral arteries, UTP and
UDP were equipotent while the stable pyrimidines dem-
onstrated a 1.5 log unit higher potency for UDPβS as com-
pared to UTPγS. UDP gave contractions in the omental
arteries with low potency, but this could not be repro-
duced by UDPβS, indicating that UDP was enzymatically
converted to UTP. Likewise, ADP induced contractions in
both cerebral and omental arteries, which could not be re-
produced by ADPβS. Thus, the endogenous nucleotides
may both underestimate and overestimate the contribu-
tion of different P2Y receptor subtypes, and previous stud-
ies using non-stable nucleotides should be interpreted
with caution.
Extracellular nucleotides are released from blood clots
during subarachnoidal haemorrhage [28,29]. Since both
UDP and UTP are particularly present in the brain and
produce sustained contraction of cerebral blood vessels,
these have been postulated to contribute in the genesis of
vasospasm after subarachnoidal haemorrhage [4,6]. The
present results that UTP and UDP were equipotent in in-
ducing contraction of cerebral arteries has also been
shown by others [4,30]. Therefore, stable nucleotides
were used to further characterise the pyrimidines sensitive
P2Y receptors that mediated this vasoconstrictor response.
In the human cerebral arteries, UDPβS was 1.5 log units
more potent than UTPγS, indicating prominent effects by
the P2Y6 receptor. Interestingly, UDPβS did not act as a
vasoconstrictor in human omental arteries, which is in ac-
cordance with a previous study of human coronary arter-
ies where UDPβS also lacked an effect [26]. It is well
known that receptor distribution varies between differentBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/4
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Figure 1
Concentration-dependent contractions to UDP, UTP, ADP and ATP in (A) human cerebral arteries and (B) human omental 
arteries. UDP, UTP, ADP and ATP were added after P2X receptor desensitisation with 10 µmol/L αβ-MeATP. Contractions 
are expressed as percentage of the response to 60 mmol/L K+. Data are shown as mean values ± S.E.M of 6 experiments 
(patients).
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Figure 2
Concentration-dependent contractions to αβ-MeATP, UDPβS, UTPγS, ADPβS and ATPγS in (A) human cerebral arteries and 
(B) human omental arteries. UDPβS UTPγS, ADPβS and ATPγS were added after P2X receptor desensitisation with 10 µmol/
L αβ-MeATP. Contractions are expressed as percentage of the response to 60 mmol/L K+. Data are shown as mean values ± 
S.E.M of 6 experiments (patients).
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vascular beds in order to obtain a specific blood flow reg-
ulation. UTP has been shown to produce prominent con-
tractions in the cerebral circulation, as compared to in the
periphery [29]. Furthermore, cerebral arteries were more
sensitive to ATP than systemic arteries from the dog heart
and mesentery [31].
The similarity in potency between ATPγS (after P2X recep-
tor desensitisation) and UTPγS suggest the presence of
contractile P2Y2 receptors in both cerebral and omental
arteries. An effect by the P2Y4 receptor cannot be excluded
since it is also activated by UTPγS. However, RT-PCR anal-
ysis could not detect P2Y4 mRNA expression in the omen-
tal arteries. These results indicate that the P2Y4 receptor is
of none or minor importance in mediating vasoconstric-
tion. Similar results have been reported from rat pial arter-
ies where mRNA transcripts for the P2Y2, but not the P2Y4
receptor could be amplified [32].
The P2Y2 effect was less prominent than that for the P2Y6
receptors in human cerebral arteries. UTP has previously
been proposed to elicit sustained vasoconstriction and va-
sospasm after subarachnoidal haemorrhage in cerebral ar-
teries [4,6]. In the present experiments, part of the UTP
may have been degraded to UDP by ectonucleotidases on
the extracellular surface of cells before eliciting vasocon-
striction. It is therefore probable that the UTP effects seen
in previous reports were really mediated by UDP sensitive
P2Y6 receptors, with a lesser contribution of UTP sensitive
P2Y2 receptors.
αβ-MeATP induced a transient contraction both in the hu-
man cerebral and omental arteries indicating the presence
of P2X receptors. Since the P2X1 receptor is rapidly desen-
sitised and has been shown to be the dominant subtype in
cerebral vascular smooth muscle cells, these are likely to
be P2X1 receptors [32,33]. In the omental arteries, αβ-
MeATP induced a transient contraction that was 2 log
units more potent than that of UTPγS and ATPγS. In the
cerebral circulation, the case was different. The αβ-MeATP
induced contraction was 1 log unit less potent than that of
UDPβS as well as 30 % less efficacious than the vasocon-
striction mediated by P2Y6 and P2Y2 receptors. Thus, con-
Table 1: Contractile responses to extracellular nucleotides in human cerebral and omental arteries.
Cerebral arteries Omental arteries
pEC50 (-log mol/L) Emax (%) pEC50 (-log mol/L) Emax (%)
αβ-MeATP 6.0 ± 0.1 80 ± 8 6.2 ± 0.1 81 ± 2
UDP 5.5 ± 0.2 128 ± 16 2.7 ± 0.2 81 ± 9
UDPβS 6.8 ± 0.2 117 ± 8 - 0 ± 0
UTP 5.3 ± 0.2 110 ± 10 3.3 ± 0.1 96 ± 8
UTPγS 5.3 ± 0.1 131 ± 10 4.3 ± 0.1 105 ± 7
ADP 2.9 ± 0.1 91 ± 23 2.6 ± 0.2 96 ± 7
ADPβS 0.0 ± 0.0 - - 8 ± 4
ATP 3.0 ± 0.2 97 ± 25 3.2 ± 0.1 88 ± 6
ATPγS 4.8 ± 0.2 125 ± 8 4.4 ± 0.1 106 ± 11
All nucleotides, except αβ-MeATP, were added after desensitisation of P2X receptors with 10 µmol/L αβ-MeATP. Contractions are expressed as 
percentage of an initial contraction induced by 60 mmol/L K+. Data are shown as Emax ± S.E.M. and pEC50 ± S.E.M of 6 experiments (patients).
Figure 3
Electrophoresis of RT-PCR products corresponding to 
mRNA encoding human P2X1, P2Y1, P2Y2, P2Y4 and P2Y6 
receptors (shown from left to right) in human cerebral and 
omental arteries. The amplified products were of the pre-
dicted size for the human P2X1 (383 base pairs), P2Y1 (550 
base pairs), P2Y2 (432 base pairs), P2Y4 (530 base pairs) and 
P2Y6 receptors (526 base pairs). Samples were analysed on a 
2% agarose / ethidium bromide gel at 5 V/cm, and 
photographed.
Omental artery Cerebral artery
500 bp –
400 bp –BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/4
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tractile P2Y receptors play a dominating role in the
cerebral circulation, as compared to the P2X receptor
effects.
The P2Y1 receptor agonist, ADPβS, had no contractile ef-
fect neither in the cerebral nor in the omental arteries.
Studies in animals demonstrate that P2Y1 receptors only
mediate endothelium-dependent dilatation in cerebral ar-
teries [32]. Furthermore, 2-MeSADP was recently shown
to induce potent dilatations in preconstricted human left
internal mammary artery branches, indicating an impor-
tant role for endothelial P2Y1 receptors [34]. This dilatory
response was abolished after the endothelium was re-
moved, providing evidence that there were no dilatory
P2Y1 receptors in these human vascular smooth muscle
cells [34]. Likewise, when the endothelium was removed
from the rat mesenteric arteries, the ADPβS induced dila-
tation was abolished [27]. PCR analysis demonstrated
presence of P2Y1 receptor mRNA. Although, the endothe-
lium was functionally removed this does not necessarily
mean that there are no endothelial cells and mRNA from
the same, which might explain the absence of effect by
ADPβS and presence of P2Y1 receptor mRNA. Also, pres-
ence of receptor mRNA does not necessarily mean there is
functional receptor-protein on the cell surface.
Our results show that the selective P2Y6 receptor agonist
UDPβS induce an efficacious and potent constriction of
human cerebral arteries, while no such effect can be
observed in human omental or coronary arteries [26].
Conversely, mRNA for P2Y6 receptors was detected in
both cerebral and omental arteries. Apparently the P2Y6
mRNA does not encode functional receptors in the omen-
tal arteries. Similar results were previously obtained in
coronary arteries [26]. Both UTP and UDP have previous-
ly proven to induce dilatation of cerebral arteries [35], al-
though when vasodilatation has been studied by use of
the stable pyrimidines, UTPγS and UDPβS, no dilatory ef-
fect of the P2Y6 receptor have be observed [26]. Taken to-
gether, it is plausible that only vasoconstriction is
mediated by P2Y6 receptors and that this effect is especial-
ly prominent in the cerebral circulation.
An interesting observation is the difference in potency in
these experiments between the endogenous (UDP and
UTP) and the stable nucleotides (UDPβS and UTPγS) and
the importance of ectonucleotidases for pyrimidine degra-
dation, as suggested by Lazarowski et al. 1997 [36]. In cell
systems, where the influence of ectonucleotidases has
been minimised, UTP and UTPγS are equally potent [18],
confirming that the increased efficacy and potency by the
stable pyrimidines in the present experiments is not due
to a structural change that alters the effect at the receptor.
Conclusions
The stable pyrimidines UTPγS and UDPβS are useful tools
in the pharmacological P2 receptor characterisation in
intact tissues with ectonucleotidase activity. Extracellular
nucleotides stimulated contractions of human cerebral ar-
teries primarily by activation of P2Y2, P2Y6 and P2X1 re-
ceptors, while a role for P2Y1 can be excluded. A similar
pattern was seen in the omental arteries, except that no
P2Y6 receptor mediated contractions was seen. These re-
sults indicate that antagonists of the P2Y6 receptor, but
also the P2Y2 and P2X1 receptors may be useful in the
treatment of vasospasm.
Methods
Patients
Cerebral and omental arteries were explanted during tu-
mour surgery from 12 patients that were between 17 and
64 years of age. The cerebral arteries looked macroscopi-
cally healthy and were removed from the temporal-pari-
etal cortex.
Table 2: Specific primers for the human P2X1, P2Y1, P2Y2, P2Y4 and P2Y6 receptors were constructed based on published nucleotide 
sequences [21–25], as follows.
Primer Nucleotide sequence Product length × (base pairs)
P2X1 forward 5'-GTTTGGGATTCGCTTTGA-3'
P2X1 reverse 5'-GGCTGAGAGGGTAGGAGAC-3' 383
P2Y1 forward 5'-ACGGGCTTCCAGTTTTAC-3'
P2Y1 reverse 5'-CCAAGGGGACACAGAACA-3' 550
P2Y2 forward 5'-CTCTGCTTCCTGCCATTC-3'
P2Y2 reverse 5'-GCACAAGTCCTGGTCCTCT-3' 432
P2Y4 forward 5'-CAGCACCAAAGGGACCAC-3'
P2Y4 reverse 5'-GCTTGCCACCACCACAGA-3' 530
P2Y6 forward 5'-ACAGGCATCCAGCGTAAC-3'
P2Y6 reverse 5'-CGGACACAATGGCAAATA-3' 526BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/4
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Vasomotor studies
Tissue preparation
The cerebral and omental arteries were immediately im-
mersed in cold oxygenated buffer solution (for composi-
tion, see below), transported to the laboratory and
dissected free from adhering tissue under a microscope.
The endothelium was removed from both the cerebral
and omental arteries by perfusion for 5 s with 0.1% Triton
X-100 followed by another 5 s of perfusion with a physi-
ologic buffer solution (for composition, see below) using
a fine needle [19]. The vessels were then cut into cylindri-
cal segments (1 mm long), and were immediately used in
the experiments. Each cylindrical segment was mounted
on two L-shaped metal prongs, one of which was connect-
ed to a force displacement transducer (FT03C) for contin-
uous recording of the isometric tension, and the other to
a displacement device [20]. The position of the holder
could be changed by means of a movable unit allowing
fine adjustments of the vascular resting tension by varying
the distance between the metal prongs. The mounted ar-
tery segments were immersed in temperature controlled
(37°C) tissue baths containing bicarbonate based buffer
solution of the following composition (mmol/L): NaCl
119, NaHCO3  15, KCl 4.6, MgCl2  1.2, NaH2PO4  1.2,
CaCl2 1.5 and glucose 5.5. The solution was continuously
gassed with 5% CO2 in O2 resulting in a pH of 7.4. Twelve
ring segments were studied at the same time in separate
tissue baths. The segments were allowed to stabilise at a
resting tension of 4 mN (omental arteries) and 2 mN (cer-
ebral arteries) for 1 h before the experiments were started.
The contractile capacity of each vessel segment was exam-
ined by exposure to a potassium-rich (60 mmol/L) buffer
solution in which NaCl was exchanged for an equimolar
concentration of KCl (for composition, see above). When
two reproducible contractions had been achieved the ves-
sels were used for further studies.
Vasomotor responses
Endothelium removal was checked by monitoring re-
sponses to acetylcholine at the end of the experiment, in
arteries preconstricted by 1 mM UTP. Abolished dilatation
indicated a properly removed endothelium [19]. The
range of acetylcholine-dilatation that can be observed
when the endothelium is intact amounts to 30–70%, for
both the human cerebral and omental arteries, depending
on the quality of the endothelium after surgery (not pub-
lished data). Unaffected K+ induced contractions indicat-
ed intact smooth muscle cell function. As the P2X
receptors were quickly desensitised, each artery segment
from both the cerebral and omental arteries was exposed
to a single concentration of αβ-MeATP and the resultant
responses of several segments exposed to different con-
centrations were added up. In this way, each artery seg-
ment was exposed to αβ-MeATP only once and the
problem of tachyphylaxia was avoided. These experi-
ments are referred to as 'single-concentration'. To study
the P2Y receptor stimulated contractions without interfer-
ence of simultaneous activation of P2X receptors, uridine
diphosphate UDP, UDPβS, UTP, UTPγS, ADP, ADPβS,
ATP and ATPγS were added after P2X receptor desensitisa-
tion with 10 µmol/L αβ-MeATP, 8 min prior to each ex-
periment. As the P2Y receptors are only very slowly
desensitised, these agonists could be added cumulatively
to determine concentration-response relationships.
The experimental protocol
First 60 mM K+ was added twice to each vessel segment.
Washout was performed for one hour both in between the
K+ induced responses and before the experiments were
started. Thereafter, one concentration of αβ-MeATP was
added to each vessel segment. When the effect of this had
been monitored for 3 min, 10 µmol/L of αβ-MeATP was
added to all vessel segments. This was left in the tissue
bath for 8 min before a P2Y receptor agonist was added in
increasing concentrations. Only one P2Y receptor agonist
was tested per arterial segment. Washout was performed
for one hour. Thereafter, 1 mM UTP was used to precon-
strict the vessel before acetylcholine was added to exam-
ine endothelium function.
RT-PCR
RNA extraction
The arteries were carefully dissected and the endothelium
was removed (see above). The arteries were snap-frozen in
liquid nitrogen immediately after acquisition and total
cellular RNA was extracted using TRIzol reagent (Gibco
BRL) following the supplier's instructions. The resulting
RNA pellet was finally washed with 70% ice-cold ethanol,
air-dried and redissolved in 10 µl diethyl-pyrocarbonate
(DEPC) treated water. The RNA concentration was deter-
mined spectrophotometrically considering a ratio of
OD260:280 ≥ 1.6 as pure.
RT-PCR
RT-PCR was carried out using the GeneAmp RNA PCR kit
(Perkin-Elmer, Foster City, CA, USA) on a GeneAmp PCR
system 2400 (Perkin-Elmer). Specific primers for the hu-
man P2X1, P2Y1, P2Y2, P2Y4 and P2Y6 receptors were con-
structed based on published nucleotide sequences [21–
25] (see Table 2).
First-strand cDNA synthesis carried out with the Amplitaq
RNA-PCR kit (Perkin Elmer) in a 20 µl volume using ran-
dom hexamers. Amplification was performed using a
modified profile (2 min at 95°C followed by 30 cycles of
1 min 95°C, 1 min 55–58°C, 30 sec. 72°C and a final ex-
tension step of 7 min at 72°C). The products were sepa-
rated on a 2% agarose gel containing 1.0 µg/mL ethidium-
bromide and photographed. The DNA Ladder 100 bp
(Promega Co.) was used as molecular weight marker. AsBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/4
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these P2 receptors are intronless within their coding
regions, PCR without the RT-step was always used to ex-
clude genomic DNA contamination.
Ethics
The project was approved by the Ethics Committee of
Lund University in Sweden.
Drugs
Vasomotor studies
Acetylcholine, ADPβS, ATP, ATPγS, UDP, UTP and αβ-
MeATP were purchased from Sigma Co. (USA). UDPβS
and UTPγS were kind gifts from Inspire Pharmaceuticals,
Inc. All drugs were dissolved in 0.9% saline.
RT-PCR
Oligonucleotides were obtained from Gibco, BRL. If not
stated otherwise, all reagents for the RT-PCR assay were
purchased from Sigma Co. (USA).
Calculations and statistics
The negative logarithm of the drug concentration that elic-
ited 50% contraction (pEC50) was determined by linear
regression analysis using the values immediately above
and below half-maximum response. Emax  refers to
maximum contraction calculated as percent of the con-
tractile capacity of 60 mmol/L K+. The experiments were
performed on arteries from six patients and statistical
significance was accepted when P < 0.05, using Student's
t-test. All differences referred to in the text have been sta-
tistically verified. Values are presented as means ± S.E.M.
RT-PCR experiments were performed on three patients.
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